Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Safety Study of Arformoterol QD Dosing Versus BID Dosing in COPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects must be at least 45 years old at the time of consent.~* Subjects must have a pre-established primary clinical diagnosis of COPD.~* Subjects must have a baseline FEV1 of ≤ 65% of predicted normal value at Visit 1.~* Subjects must have a FEV1 ≥ 0.70L at Visit 1.~* Subjects must have a FEV1/forced vital capacity (FVC) ratio of ≤ 70% at Visit 1.~Exclusion Criteria:~* Subjects who do not have a 15 pack-year smoking history and a baseline breathlessness severity grade of 2 (as measured by the Modified Medical Research Council \[MMRC\] Dyspnea Scale Score) at Screening.~* Subjects with life-threatening/unstable respiratory status, including upper or lower respiratory tract infection, within the previous 30 days prior to Visit

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 15 mcg BID / 30 mcg QD (Type: EXPERIMENTAL): Arformoterol 15 microgram twice a day (BID) taken each morning and evening for one visit followed by Arformoterol 30 microgram once a day (QD) in the morning and placebo in the evening for the next visit.
- 30 mcg QD / 15 mcg BID (Type: EXPERIMENTAL): Arformoterol 30 microgram once a day (QD) in the morning and placebo in the evening for one visit followed by Arformoterol 15 microgram twice a day (BID) in the morning and evening for the next visit.

Based on this trial design, predict the completion outcome and termination type (if applicable).